Coronavirus / COVID

New international analysis highlights successes—and shortcomings—among Pacific Asia and European regions who began to reopen their societies.

Dr. Rodney E. Rohde, clinical laboratory scientist, discusses campus reopening as well as his work on rabies eradication.

The EUA grants clinicians and caregivers capability to provide serologic assay results in person to potentially infected patients.

The Chinese government approves trial for Sinovac's vaccine in these patient populations.

In the second survey in a series, more respondents said they were wearing face coverings, less would get vaccinated, and there was a slight increase in their fears about the severity of the disease.

Is it still safe to take your child to get a vaccine during the pandemic? According to experts, there are safety measures in place for this critically important task.

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

A small study is reporting very few adverse effects and low rates of COVID-19 transmission rates from mother to baby.

A small study in Italy suggests that children are less likely than adults to be asymptomatic spreaders of COVID-19.

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

Rheumatologists are understandably concerned regarding immune suppressed patients amid the coronavirus (COVID-19) pandemic. What are the risk factors for hospitalization? And do drugs which act against inflammation complicate matters?

On Friday, new guidelines from CDC sought to show how the pandemic coronavirus (COVID-19) spreads. By Monday, those guidelines changed.

Dr. Shervin Molayem, DDS, continues our discussion on his recent paper The Mouth-COVID Connection: Il-6 Levels in Periodontal Disease — Potential Role in COVID-19-Related Respiratory Complications.

The country successfully managed thousands of mild cases among foreign construction workers at the height of the pandemic through an isolation facility. It may not be an applicable model, though.

A pediatric cardiologist discusses the specifics of a case study, the importance of adaptability, and how her healthcare system has developed treatment protocols in these cases.

Medical science needs to understand the disease more clearly in this understudied patient population.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

Do the norms of media coverage of SARS-CoV-2 worsen rising acute stress and depressive symptoms in the United States?

The guidance clarification published today comes just a day after reports a polarizing guidance was published last month without full review nor consensus from the agency.

Antibodies are just one part of the body's immune response. And growing evidence suggests many of us could already have cross-reactive cellular immunity to the “novel” coronavirus.

Dr. Shervin Molayem, DDS, outlines his recent paper The Mouth-COVID Connection: Il-6 Levels in Periodontal Disease — Potential Role in COVID-19-Related Respiratory Complications.

Scans typically used to diagnose strokes are showing physical signs in the lungs that identify COVID-19.

A new study adds to growing concern about short immunity duration and the potential for reinfection.

Officials state the controversial August guidance was influenced by other federal agencies, and that revisions may come soon.

A health data analytics expert describes how repeat or low-value studies can arise amid the rush to publish pandemic research.

An editorial advocating a new method of CRISPR testing was published in NEJM by a team of scientists from MIT, University of Washington, and Brigham & Women’s Hospital.

MediFind's Patrick Howie examines the consolidation of resources during pandemics amid concerns that funding will not return to other areas of health research.

A look into the long-term implications of the virus on athletes' cardiovascular fitness.

What we've seen non-immunized communities do for previously eradicated outbreaks.

Eli Lilly’s investigational therapy, LY-CoV555, was shown to be well-tolerated and met its primary endpoint for one of its doses.